Paul Calabresi Career Development Award for Clinical Oncology (K12) at UC Davis

 描述(由申请人提供)：加州大学戴维斯分校保罗·卡拉布雷西K12临床肿瘤学研究职业发展计划(CDP；PI，Primo Lara，Jr.)的总体目标。医学博士)是将临床医生或基础-翻译初级教员培养成独立的、以患者为导向的癌症研究人员，他们在翻译、团队驱动的研究方面受到过高度培训。利用1)核心能力，2)高级肿瘤学课程，3)职业发展，4)指导研究，5)跨文化接触，CDP每年提供两名新学者(任何时候六名)的培训，旨在磨练远远超出他们最初学科界限的想法和技能。学者们将克服临床研究人员和基础翻译研究人员之间通常存在的语言和文化障碍，利用加州大学戴维斯分校的协作研究环境，参加多学科和翻译论坛，并收集研究设计、临床试验开发、团队科学、赠款撰写、研究道德行为、沟通和职业发展方面的基本技能。我们的愿景是通过培训临床医生研究人员在他们追求临床试验时纳入和利用基础/相关科学来加强转化研究(“临床跟踪”)，并反过来推动基础科学工作者转向以患者为导向的药物开发和临床研究(“基础/转化跟踪”)。为了保持对以患者为导向的临床研究的重视，所有CDP学者在临床导师和基础/翻译导师的指导下，将被要求在培训期间开发和启动/进行他们自己的由研究人员发起的临床试验。该计划将利用NCI指定的加州大学戴维斯综合癌症中心、NCATS资助的临床和翻译研究中心(CTSC)以及医学院职业发展计划的杰出研究、培训和评估专业知识和基础设施。它将由一个组织严密的内部监督委员会和外部咨询委员会进行监督和加强。总体而言，CDP试图实现以下具体目标：1)提供基于能力的教学课程，以促进团队科学，鼓励翻译研究，并磨练临床试验开发的基本技能 该中心的职能包括：2)监督针对每个学者的兴趣和需求定制的以患者为导向的个性化研究项目；3)监督学者培训，以确保逐步培养一支完全胜任的跨学科研究人员队伍，他们能够成功地使用新的研究试剂或设备进行转化性癌症临床试验。这些具体目标将使加州大学戴维斯分校建立一支训练有素的研究人员队伍，走在创新、有影响力的循证研究的前沿，他们可以监督涵盖从基础科学(靶标识别和药物发现)到转化科学(药物开发和相关科学)再到临床研究的整个研究连续体的研究。通过这样做，我们提供了潜在的 既提高了临床科学家的成功，又改善了癌症患者的预后。

 DESCRIPTION (provided by applicant): The overarching goal of the UC Davis Paul Calabresi K12 Clinical Oncology Research Career Development Program (CDP; PI, Primo Lara, Jr. MD) is to nurture clinician or basic-translational junior faculty to become independent, patient-oriented cancer researchers who are highly trained in translational, team-driven research. Using 1) core competencies, 2) advanced oncology coursework, 3) career development, 4) mentored research, and 5) cross-cultural exposure, the CDP provides two new scholars per year (six at any one time) with training aimed at honing ideas and skills that go far beyond their initial disciplinary boundaries. Scholars will overcome language and cultural barriers that typically exist between clinical and basic-translational researchers, take advantage of the collaborative research environment at UC Davis, participate in multidisciplinary and translational forums, and gather essential skills in research design, clinical trial development, team science, grant writing ethical conduct of research, communication, and career development. The vision is to enhance translational research by training clinician researchers to incorporate and utilize basic/correlatie science in their pursuit of clinical trials ("Clinical Track"), and conversely, driving basic scienists towards patient-driven drug development and clinical research ("Basic/Translational Track"). To maintain the emphasis on patient- driven clinical research, all CDP scholars, under the mentorship of both a clinical mentor and basic/translational mentor, will be required to develop and initiate/conduct their own investigator-initiated clinical trial during the training period. Th program will leverage the outstanding research, training, and evaluation expertise and infrastructure of the NCI-designated UC Davis Comprehensive Cancer Center, NCATS-funded Clinical and Translational Research Center (CTSC), and School of Medicine Career Development Program. It will be overseen and enhanced by a highly organized internal Oversight Committee and external Advisory Board. Overall, the CDP seeks to accomplish the following specific aims: 1) Offer a competency-based didactic curriculum to promote team science, encourage translational research, and hone essential skills for clinical trial development and career/research success; 2) Oversee individualized patient- oriented research projects customized to the interests and needs of each scholar; and 3) Provide oversight of scholar training to ensure the progressive development of a cadre of fully competent interdisciplinary-oriented researchers who can successfully conduct translational cancer clinical trials with investigational new agents or devices. These specific aims will enable the building of a critical mass of trained researchers at UC Davis at the forefront of innovative, impactful, evidence-based research, who can oversee research that encompasses the entire continuum of research from basic science (target identification and drug discovery) through translational science (drug development and correlative science) to clinical investigation. By doing so, we offer the potential of both enhancing the success of clinician scientists and improving outcomes for cancer patients.